Tanzeum (Subcutaneous)
Tanzeum (Subcutaneous) Uses, Dosage, Side Effects, Food Interaction and all others data.
Tanzeum (Subcutaneous) is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Tanzeum (Subcutaneous) was approved on April 15, 2014 by the FDA.
| Trade Name | Tanzeum (Subcutaneous) |
| Availability | Prescription only |
| Generic | Albiglutide |
| Albiglutide Other Names | Albiglutida, Albiglutide |
| Related Drugs | Farxiga, metformin, Trulicity, Lantus, Victoza, Tresiba, Levemir |
| Type | |
| Formula | C3232H5032N864O979S41 |
| Weight | 72970.0 Da |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | USA |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Tanzeum (Subcutaneous) is a GLP-1 agonist used to manage type 2 diabetes mellitus.
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Tanzeum (Subcutaneous) is also used to associated treatment for these conditions: Type 2 Diabetes Mellitus
How Tanzeum (Subcutaneous) works
Tanzeum (Subcutaneous) is an agonist of the GLP-1 (glucagon-like peptide 1) receptor and augments glucose-dependent insulin secretion. Tanzeum (Subcutaneous) also slows gastric emptying.
Toxicity
-RISK OF THYROID C-CELL TUMORS -Tanzeum (Subcutaneous) is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value in patients treated with Tanzeum (Subcutaneous).
Food Interaction
[Moderate] MONITOR: Glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists delay gastric emptying, which may impact the absorption of concomitantly administered oral medications.
Mild to moderate decreases in plasma concentrations of coadministered drugs have been demonstrated in pharmacokinetic studies for some GLP-1 receptor agonists (e.g., exenatide, lixisenatide), but not others.
The impact of dual GLP-1 and GIP receptor agonist tirzepatide on gastric emptying was reported to be greatest after a single dose of 5 mg but diminished after subsequent doses.
According to the prescribing information, liraglutide did not affect the absorption of several orally administered drugs to any clinically significant extent, including acetaminophen, atorvastatin, digoxin, griseofulvin, lisinopril, and an oral contraceptive containing ethinyl estradiol-levonorgestrel.
Likewise, no clinically relevant effect on absorption was observed for concomitantly administered oral drugs studied with albiglutide (digoxin, ethinyl estradiol-norethindrone, simvastatin, warfarin), dulaglutide (acetaminophen, atorvastatin, digoxin, ethinyl estradiol-norelgestromin, lisinopril, metformin, metoprolol, sitagliptin, warfarin), or semaglutide (atorvastatin, digoxin, ethinyl estradiol-levonorgestrel, metformin, warfarin).
In addition, coadministration of acetaminophen after a first dose of tirzepatide 5 mg reduced the acetaminophen peak plasma concentration (Cmax) by 50% and delayed its median time to peak plasma concentration (Tmax) by 1 hour, but no significant impact on Cmax and Tmax was observed after coadministration at week 4, and the overall exposure of acetaminophen was unaffected.
Nevertheless, potential clinical impact on other oral medications cannot be ruled out, particularly those with a narrow therapeutic index or low bioavailability, those that depend on threshold concentrations for efficacy (e.g., antibiotics), and those that require rapid gastrointestinal absorption (e.g., hypnotics, analgesics).
br>
MANAGEMENT: Pharmacologic response to concomitantly administered oral medications should be monitored more closely following the initiation or discontinuation of treatment with a GLP-1 receptor agonist or a dual GLP-1 and GIP receptor agonist.
Tanzeum (Subcutaneous) Alcohol interaction
[Moderate] GENERALLY AVOID:
Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.
Hypoglycemia most frequently occurs during acute consumption of alcohol.
Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.
The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.
Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.
By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.
[Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.
A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.
Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.
Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.
Alcohol should not be consumed on an empty stomach or following exercise.
Tanzeum (Subcutaneous) Drug Interaction
Moderate: formoterol / mometasone, insulin detemirUnknown: lactobacillus acidophilus, aspirin, aspirin, aspirin, amoxicillin / clavulanate, nebivolol / valsartan, tadalafil, clonidine, docusate, secukinumab, duloxetine, glucose, emollients topical, sumatriptan, infliximab, escitalopram, methyl salicylate topical, acetaminophen / hydrocodone
Tanzeum (Subcutaneous) Disease Interaction
Major: pancreatitis, thyroid carcinomaModerate: renal dysfunction
Volume of Distribution
11 L.
Elimination Route
Maximum concentrations of albiglutide were reached at 3 to 5 days post-dosing following a single 30mg dose. The mean peak concentration (Cmax) and mean area under the time-concentration curve (AUC) of albiglutide were 1.74 mcg/mL and 465 mcg.h/mL, respectively
Half Life
4-7 days.
Clearance
67 mL/h.
Innovators Monograph
You find simplified version here Tanzeum (Subcutaneous)
FAQ
What is Tanzeum (Subcutaneous) used for?
Tanzeum (Subcutaneous) is used with a diet and exercise program to control blood sugar levels in adults with type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood) when other medications did not control.
How is Tanzeum (Subcutaneous) administered?
Tanzeum (Subcutaneous) is administered by subcutaneous injection, once weekly with or without food, beginning with the 30-mg dose and increasing to 50 mg. Patients will need to prepare the product 15 to 30 minutes before injection using supplied materials and instructions.
What are the common side effect Tanzeum (Subcutaneous)?
Commonly reported side effects of Tanzeum (Subcutaneous) include: injection site reaction, diarrhea, and nausea.Other side effects include:
- Bloating
- chills or fever
- darkened urine
- fast heartbeat
- loss of appetite
- nausea, vomiting, or indigestion
- pains in the stomach, side, or abdomen, possibly radiating to the back
Is Tanzeum (Subcutaneous) safe during pregnancy?
This Tanzeum (Subcutaneous) should not be used during pregnancy unless the benefit outweighs the risk to the fetus.
Is Tanzeum (Subcutaneous) safe during breastfeeding?
A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the Tanzeum (Subcutaneous) to the mother.
What is the best time of day to take Tanzeum (Subcutaneous)?
Tanzeum (Subcutaneous) is best to take your doses at the same time of day each day. Swallow the tablet with a drink of water -you can take it either with or without food.You can generally take Tanzeum (Subcutaneous) at a time of day to suit you.
How safe is Tanzeum (Subcutaneous)?
Tanzeum (Subcutaneous) may increase the risk of heart failure, particularly in patients who already have heart or kidney disease.
How long does it take for Tanzeum (Subcutaneous) to start working?
Tanzeum (Subcutaneous) could take 18 to 20 weeks before you see the full effects of this medication on lowering your blood sugar and improving your A1c level.
Can I drink alcohol with Tanzeum (Subcutaneous)?
Alcohol may affect blood glucose levels in patients with diabetes. You should avoid using alcohol if your diabetes is not well controlled or if you have high triglycerides, neuropathy (nerve damage), or pancreatitis. Moderate alcohol consumption generally does not affect blood glucose levels if your diabetes is under control.
How should I use Tanzeum (Subcutaneous)?
Tanzeum (Subcutaneous) is injected under the skin. A healthcare provider may teach you how to properly use the medication by yourself.
Is Tanzeum (Subcutaneous) safe for kidney disease?
Our study suggests that Tanzeum (Subcutaneous) can be safely administered in patients with CKD. Tanzeum (Subcutaneous) to demonstrate renal protective effects, were unable to detect statistically significant differences.
Does Tanzeum (Subcutaneous) cause muscle pain?
Tanzeum (Subcutaneous) may cause severe and disabling joint pain.Call your doctor right away if you have severe joint pain while using this medicine.
Can I overdose on Tanzeum (Subcutaneous)?
If you take too much Tanzeum (Subcutaneous), call your healthcare provider or local Poison Control Center, or seek emergency medical attention right away. If Tanzeum (Subcutaneous) is administered by a healthcare provider in a medical setting, it is unlikely that an overdose will occur.
Does Tanzeum (Subcutaneous) cause swelling?
Tanzeum (Subcutaneous) can cause heart failure and cause your body to keep extra fluid (fluid retention), which leads to swelling and weight gain.
Does Tanzeum (Subcutaneous) cause fatigue?
Severe stomach pain that may move to your back,vomiting,excessive tiredness,loss of appetite.
Can Tanzeum (Subcutaneous) cause palpitations?
The first signs of hypoglycaemia are feeling shaky or anxious, sweating, looking pale, feeling hungry, having a feeling that your heart is pounding (palpitations), and feeling dizzy.
